Suggested remit - To appraise the clinical and cost effectiveness of brolucizumab within its marketing authorisation for treating wet age-related macular degeneration.
 
Status In progress
Process STA 2018
ID number 1254

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group Warwick Evidence, Warwick Medical School, University of Warwick

Consultees

Companies sponsors Novartis (brolucizumab)
Others Department of Health and Social Care
  NHS England
  NHS Luton
  Welsh Government
Patient carer groups Macular Society
Professional groups Royal College of Ophthalmologists
  Royal College of Pathologists
  Royal College of Physicians
  UK Ophthalmic Pharmacy Group

Commentators

Comparator companies Bayer Pharma (aflibercept) (confidentiality agreement signed, participating)
  Novartis (ranibizumab) (confidentiality agreement signed, participating)
  Roche (bevacizumab) (confidentiality agreement not signed, not participating)
General commentators British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
27 August 2019 Invitation to participate
27 August 2019 In progress, In progress
29 January 2019 - 26 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance